Life Technologies Acquires KDR Biotech

Life Technologies Corporation

today announced the acquisition of KDR Biotech Co., Ltd., (KDR Biotech) a leading reagents distributor based in Seoul, Korea. KDR Biotech has been Life's primary reagent distributor in Korea since 1982. The Korean biotechnology market has high potential—showing solid growth over the past five years and with the Korean government's Bio-vision 2016 initiative, it's anticipated to drive further growth in biotechnology investments within the country. "The acquisition of KDR Biotech is in line with Life's Asia-Pacific Japan strategy to further develop customer relationships, improve the customer experience and increase revenue in the fast-growing South Korean biotechnology market, in addition to Life's overall strategy of expanding our footprint into strong growth and emerging markets," said Mark Smedley, president of Life Technologies, Asia-Pacific Japan region. "KDR Biotech will help us build a strong, leading brand in South Korea to propel us forward into sustainable growth." Currently, KDR Biotech offers a complete solution to serve the many different needs of South Korean life science customers in academia, government research and within the industry. KDR Biotech's 30 years of market knowhow and experience in building customer relationships will assist in Life reaching out to an even larger customer base in the life science market in Korea. Life will also continue to offer non-Life products which had been part of KDR Biotech's portfolio, such as plastic ware and other complementary life science products which will maintain a competitive advantage in direct sales and to enhance the customer experience. All current KDR Biotech employees in the main office in Seoul and throughout Korea will become part of Life Technologies Korea and CEO, Mr. Jong-moon (Arnold) Kim, will also serve as an external advisor to Life Technologies during the transition. Other terms of the acquisition are not being disclosed. About Life Technologies Life Technologies Corporation

is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012. Life Technologies' Safe Harbor Statement This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.